In the HCC tissues, our data demonstrated that CPEB2 was significantly downregulated, and its lack of expression was linked to poor clinical outcomes, including tumor recurrence and vascular invasion, which is consistent with the findings already reported in previous studies [24]. Here, CPEB2 is linked to hepatocellular carcinoma.